Drug intelligence / Profile preview

alteplase + edaravone

Development stage
Phase 4
Lead developer
Ruijun Ji
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Intravenous, Sublingual
01

Overview

alteplase + edaravone is a combination therapy being evaluated for the treatment of acute ischemic stroke (AIS). This regimen combines the thrombolytic agent alteplase (a recombinant tissue plasminogen activator) with edaravone, a neuroprotective free radical scavenger. In the Phase 4 EXCELLENT trial led by Ruijun Ji, this combination is administered ultra-early in a mobile stroke unit (MSU) setting. Alteplase is delivered intravenously to dissolve the causative blood clot by converting plasminogen to plasmin, while edaravone is administered sublingually to mitigate oxidative stress and neuronal damage associated with ischemia and subsequent reperfusion. The study specifically evaluates whether this early neuroprotection can improve clinical outcomes and reduce hemorrhagic transformation following revascularization.

Other names
t-PA + edaravonetissue plasminogen activator + edaravoneintravenous thrombolysis + edaravone
02

Targets

Fibrin (Factor Ia)PLG (Plasminogen)

Beyond the preview

Go deeper on alteplase + edaravone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alteplase + edaravone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call